Trial Profile
INTENT: immunogenicity in patients failing response on anti-TNF -Immunogenicity and pharmacokinetics in patients failing to respond to TNF inhibitors (phase 1); -Clinical effectiveness of subsequent TNF inhibitor treatment and predictive value of pharmacokinetics and immunogenicity (phase 2)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Adalimumab; Certolizumab pegol; Golimumab; Infliximab
- Indications Ankylosing spondylitis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Pharmacodynamics
- Acronyms INTENT
- 01 Oct 2015 New trial record